Table 2.
Baseline characteristics of patients treated with partial enteral nutrition + modified Crohn’s disease exclusion diet (PEN + mCDED) and exclusive enteral (EEN) nutrition.
| PEN + mCDED (n = 13) |
EEN (n = 16) |
p | |
|---|---|---|---|
| Age at inclusion (median, IQR) | 14.0 (4.5) | 14.1 (3.8) | 0.726 |
| Male, n (%) | 8 (61.5) | 6 (37.5) | 0.198 |
| Newly diagnosed, n (%) | 6 (46.1) | 12 (75.0) | 0.143 |
| Paris classification [57] Age at diagnosis n (%) |
0.455 | ||
| A1a (<10 years) | 3 (23.1) | 2 (12.5) | - |
| A1b (10–17 years) | 10 (76.9) | 12 (75.0) | - |
| A2 (>17 years) | 0 (0) | 2 (12.5) | - |
| Location, n (%) | 0.948 | ||
| L1—ileal/ileocecal | 1 (7.7) | 0 (0) | - |
| L2—colonic | 4 (30.7) | 7 (43.8) | - |
| L3—ileocolonic | 8 (61.6) | 9 (56.2) | - |
| L4a | 11 (84.6) | 12 (75.0) | - |
| L4b | 3 (23.1) | 2 (12.5) | - |
| L4ab—L4a + L4b | 3 (23,1) | 2 (12.5) | - |
| Duration of nutritional treatment (days) | 47.5 (5.5) | 49.3 (8.1) | 0.505 |
| Maintenance therapy at baseline, n (%) | |||
| IMM only | 5 (38.5) | 4 (25.0) | |
| Azathioprine + anti-TNF | 1 (7.7) | 0 | |
| Vedolizumab | 1 (7.7) | 0 | |
| ESR | 38.3 (7.0) | 35.8 (5.6) | 0.544 |
| CRP | 23.0 (6.6) | 17.2 (2.9) | 0.566 |
| Baseline PCDAI score | 31.2 (2.7) | 31.1 (2.8) | 0.544 |
| Baseline SES-CD score | 13.2 (1.5) | 10.8 (1.4) | 0.247 |
Abbreviations: PEN + mCDED, partial enteral nutrition + modified Crohn’s disease exclusion diet; EEN, exclusive enteral nutrition; IQR, interquartile range; IMM, immunomodulator; anti-TNF, anti-tumour necrosis factor; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PCDAI, paediatric Crohn’s disease activity index; SES-CD, simple endoscopic score for Crohn’s disease. ESR, CRP, PCDAI, and SES-CD are presented as the mean and standard error.